Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
P/S ratio for Keros Therapeutics, Inc. (KROS)
P/S ratio as of 2023: 7753.76
According to Keros Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7753.76. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for Keros Therapeutics, Inc. from 2018 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 7753.76 |
| 2022 | 0.00 |
| 2021 | 67.92 |
| 2020 | 0.00 |
| 2019 | 17.84 |
| 2018 | 17.84 |